2.Adjuvant chemotherapy of stage Ⅱ colon cancer
Journal of International Oncology 2013;(6):463-465
For stage Ⅱ colon cancer patients after surgery,the benefit of adjuvant chemotherapy remains controversial.Several studies indicate that the patients with high-risk stage Ⅱ colon cancer can benefit from adjuvant chemotherapy after surgery.According to the clinical and pathological features,the stage Ⅱcolon cancer patients including T4 lesion,perforation,peritumoral lymphovascular invasion can benefit from the adjuvant chemotherapy of oxaliplatin.In the horizontal of molecular and genetic levels,the stage Ⅱ colon cancer patients can express high microsatellite instability (MSI-H) and cannot benefit from the chemotherapy of Fluorouracil.The guiding functions of 18q loss of heterozygosity (18q LOH),Cx43 and gene expression profiling in adjuvant chemotherapy are still unclear,and need further study.
3.Utility of Fluoxetine in Treating Tinnitus Patients
Journal of Audiology and Speech Pathology 1998;0(02):-
Objective To evaluate t he efficacy of fluoxetine in treating tinnitus patients with depress. Methods A randomized,open-labeled,controlled clinical tri al was conducted.There were 31 patients in control group and 26 p a tents in fluoxetine group.The efficacy was assessed by tinnitus patients with Ra ting Scale and Hamilton Depression Rating Scale (HAMD). Results The total effective rate of fluoxetine group was 71.11%, and there was significant improvement rate in depression after 1 month f luoxetine treatm ent. Conclusion Fluoxetine is an effective drug for tinnitus p atients with depression.
4.Preparation of transferrin and RGD co-modified PLGA nanoparticles and its targeting to melanoma
Chinese Journal of Biochemical Pharmaceutics 2014;37(4):19-21
Objective To prepare transferrin and Arg-Gly-Asp polypeptide co-modified nanoparticles(TF/RGD-NPs)and evaluate its targeting efficiency to melanoma.Methods The co-modified nanoparticles were prepared by emulsion method and its appearance,particle size and Zeta potential were evaluated.The cellular uptake experiment and melanoma tumor spheroids penetration test were used to evaluate the affinity and ability to penetrate tumor tissues of TF/RGD-NPs to melanoma B16 cells. Results The particle diameter of co-modified nanoparticles was(113.4 ±12.5)nm and the Zeta potential was(4.53 ±2.15)mV.In vitro uptake test demonstrated that the efficacy of cellular uptaken TF/RGD-NPs by B16 cells were 2.7 times and 2.9 times to TF-NPs and RGD-NPs,respectively,the differences were all significant(P<0.05 ).Tumor spheroid penetration test results showed that TF/RGD-NPs has good affinity to melanoma cells.Conclusion TF/RGD-NPs can target to melanoma B16 cell efficiency in vitro,it may be serve as a potential drug delivery system for targeting melanoma.
5.Exploration of personnel training mode in local medical and health vocational colleges under the guidance of modern occupation education ideas
Chinese Journal of Medical Education Research 2012;11(3):236-238
Taking the modern occupation education concept as the guide,oriented by adapting to the demand of occupation post,we established a new open education mechanism of medical occupation education to promote the reform of personnel training mode,curriculum and teaching content to explore the effective way of the sustainable development of local medical occupation education.
6.On the compensation mechanism for urban medical services
Chinese Journal of Hospital Administration 2009;25(5):297-301
Reform on medial service compensation mechanism,as a key point in the heahhcare system reform,runs through the entire reform process.It plays a key role for the establishment and improvement of urban medical care system,medical service system,medical management system and operating system,for its guidance and regulation effects.Such a refonn to build a scientific and perfect compensation model and mechanism will be highly significant for the smooth progress of the new round of healthcare reform and its success in the end.
7.Radiotherapy in the treatment of uterine sarcomas
Chinese Journal of Obstetrics and Gynecology 2001;36(3):159-161
Objective To study radiotherapy in the treatment of uterine sarcomas and response to radiation in primary or recurrent uterine sarcomas. Methods A total of 102 uterine sarcomas treated in the Cancer Hospital from May 1960 to June 1999. A retrospective review of 45 patients receiving surgery alone, 29 patients for postoperative radiotherapy, 4 radiotherapy alone, 24 recurrent sarcomas receiving radiotherapy. Results The 5-year overall survival for 45 patients treated with surgery alone and 29 patients managed by postoperative radiotherapy were 56.7% and 58.6% respectively (P>0.05). The addition of radiotherapy significantly reduced the local recurrence rate from 42.2% to 20.7% (P<0.05). The tumor was disappeared completely by treatment of radiotherapy alone in 3 patients of primary uterine cervix sarcomas. 1 patient was free of disease at 36 months. Other 2 patients died 9 and 11 months later because of distant metastases. The complete and partial response rate of radiotherapy was 50.0% for recurrent tumors. The radiotherapetic sensibility of endometrial stromal sarcomas, mixed mesodermal sarcomas and leiomyosarcomas was downward tendency in turn.Couclusions The postoperation adjuvant radiotherapy reduced the pelvic recurrent significantly. Radiotherapy should be used in the treatment of uterine sarcomas as an important part of combination therapy.
10.Transient receptor potential channels 6 in tumor
Journal of International Oncology 2011;38(9):656-659
Transient receptor potential (TRP) is a kind of novel Ca2+ permeant channel.It is later found that TRP channels are expressed broadly in many organisms,tissues and cell types.It is involved in the regulation of sensory conduction and cell signal transduction.Further studies are required to assess which TRPC6(a member of TRPC subfamily) is associated with the cytosolic Ca2+ levels,development and progression of cancer and tumor cell cycle.TRPC6 may be regarded as new targets for the treatment of cancer.